|Bid||216.75 x 1000|
|Ask||217.20 x 1200|
|Day's range||214.48 - 218.44|
|52-week range||214.48 - 296.67|
|Beta (5Y monthly)||0.64|
|PE ratio (TTM)||14.75|
|Earnings date||02 Aug 2023 - 07 Aug 2023|
|Forward dividend & yield||8.52 (3.93%)|
|Ex-dividend date||17 May 2023|
|1y target est||254.55|
Investors need to pay close attention to Amgen (AMGN) stock based on the movements in the options market lately.
When you think of Johnson & Johnson (NYSE: JNJ), you may think of shampoo and Band-Aids. In fact, J&J is in the process of spinning off that business into an entity called Kenvue. What is J&J's top revenue driver?
The Federal Trade Commission (FTC) has been taking a much more adversarial approach to mergers and acquisitions lately. For instance, it recently said it plans to block the pending deal between pharmaceutical companies Horizon Therapeutics (NASDAQ: HZNP) and Amgen (NASDAQ: AMGN). Does the FTC's recent tough stance on big deals increase the chances that Pfizer's (NYSE: PFE) acquisition of Seagen (NASDAQ: SGEN) will also run into problems?
Here is your Pro Recap of 4 head-turning deal dispatches you may have missed this week: potential block of Horizon/Amgen transaction, merger deals at Magellan Midstream/Oneok and Urstadt Biddle/Regency Centers, and New Relic’s potential $5B acquisition. InvestingPro subscribers got this news before anyone else. Horizon Therapeutics (NASDAQ:HZNP) shares plunged more than 14% on Tuesday after the report that the U.S. Federal Trade Commission (FTC) is expected to introduce a lawsuit to block the proposed $27.8 billion merger with Amgen (NASDAQ:AMGN).
As the EU approved Microsoft’s $75bn bid to buy Activision Blizzard, the US Federal Trade Commission sued to block Amgen’s $28.3bn deal to acquire Horizon Therapeutics and warned of “rampant consolidation” in pharmaceuticals. Margrethe Vestager, EU competition commissioner, is known as the nemesis of Big Tech but others are taking her place. The Amgen suit epitomises the tough approach adopted by Lina Khan, chair of the FTC, and Khan has a new ally: Sarah Cardell, chief executive of the UK Competition and Markets Authority.
Inflation rates may finally be cooling down from last year's unnerving levels. Plenty of dividend-paying companies are dishing out -- and growing -- their dividend payments generously enough to outpace inflation's impact. Here's a closer look at three such dividend stocks to consider adding to the income-paying portion of your portfolio.
Shares of the clinical-stage metabolic disorder specialist Viking Therapeutics (NASDAQ: VKTX) were down by 6.45% on moderate volume as of 1:42 p.m. ET Thursday afternoon. Small- and mid-cap biotech stocks are under pressure today following the Federal Trade Commission's (FTC) decision to sue over the proposed merger between Amgen and Horizon Therapeutics earlier this week. Before investors get too concerned, however, it's important to understand what's actually driving this takeover speculation.
WASHINGTON (Reuters) -The U.S. Supreme Court on Thursday ruled against Amgen Inc in its bid to revive patents on its cholesterol-lowering drug Repatha in a legal clash with French rival Sanofi SA. The 9-0 ruling upheld a lower court's decision that had invalidated Amgen's patents on the grounds that the Thousand Oaks, California-based drugmaker had failed to provide a roadmap for recreating, or "enabling," the full scope of its claimed innovation. Conservative Justice Neil Gorsuch wrote for the court that "we agree with the lower courts that Amgen has failed to enable all that it has claimed, even allowing for a reasonable degree of experimentation."
Hennion & Walsh CIO Kevin Mahn joins Yahoo Finance Live to discuss the state of the consumer amid retail earnings, Target Q1 earnings, Walmart earnings preview, Fed rate hikes, inflation, and the impact on consumer spending.
A senior Pfizer executive has warned that a crackdown on mergers and acquisitions by antitrust regulators would be a “disaster” for the system of innovation that underpins the pharmaceutical industry. William Pao, Pfizer’s chief development officer, said M&A is an important part of the funding ecosystem that supports the development of innovative therapies by scientists. “If you can’t get those M&A [deals] and then get those molecules distributed across the globe, it stifles innovation for sure,” said Pao, who heads the Pfizer arm responsible for clinical development of drugs and ensuring a pipeline of new therapies.
Per the FTC, Amgen's (AMGN) acquisition of Horizon (HZNP) would entrench the monopoly positions for the latter's medications for thyroid eye disease and chronic refractory gout.
No deal is fully inoculated against regulatory intervention. In December, biopharmaceutical firm Amgen announced the acquisition of biotech star Horizon Therapeutics for $116.50 per share or $28bn in aggregate. On Tuesday, the US Federal Trade Commission sued to block the deal.
Pfizer (PFE) offers bonds worth $31 billion to fund its pending acquisition of cancer drugmaker, Seagen (SGEN).
Deal or no deal? That's now the big question for investors concerning Amgen's (NASDAQ: AMGN) pending $28 billion acquisition of Horizon Therapeutics (NASDAQ: HZNP). The Federal Trade Commission (FTC) announced on Tuesday that it has filed a lawsuit to prevent this buyout from happening.
Replacing Pfizer (NYSE: PFE) as a component of the Dow Jones Industrial Average nearly three years ago, the pharmaceutical company Amgen (NASDAQ: AMGN) is among the best dividend payers in its industry. Let's dig into Amgen's fundamentals and valuation to get an answer to this question. With around 24,000 employees in total, Amgen is a major drugmaker with a $124 billion market capitalization.
This is an audio transcript of the FT News Briefing podcast episode: ‘US sues to block drug merger’Marc Filippino Good morning from the Financial Times. Today is Wednesday, May 17th, and this is your FT News Briefing.
The Regeneron chief executive has backed an attempt by US regulators to block Amgen’s $28bn acquisition of Horizon Therapeutics as he accused some pharmaceutical companies of abusing their market power to prevent competition. Leonard Schleifer said he supported the US Federal Trade Commission’s decision to tackle a “new area” after the agency made its first attempt to block a pharma deal in over a decade by filing a novel lawsuit against the Amgen transaction. Schleifer said it can be hard to for a drugmaker get a treatment covered by payers if they are receiving “billions and billions of dollars” in rebates from a rival company.
Big Pharma needs an antitrust antidote. The Federal Trade Commission and its hard-nosed chair Lina Khan have struck again, this time filing a...
The Yahoo Finance Live team breaks down Tuesday's biggest stories, including Home Depot earnings report, the FTC suing to block Amgen's deal to buy Horizon Therapeutics, and Comcast's talks to sell its Hulu stake to Disney.
The Yahoo Finance Live team discusses stocks to watch at the closing bell, including Lowe's, Horizon Therapeutics, AMD, and Nvidia.
Yahoo Finance healthcare reporter Anjalee Khemlani joins the Live Show to discuss details surrounding the FTC suing biopharmaceutical giant Amgen Inc and its plan to block Amgen's $27.8 billion deal to acquire Horizon Therapeutics.
Unconfirmed reports suggest that the FTC may challenge the $28-billion buyout of Horizon Therapeutics (HZNP) by Amgen.
Although the Nasdaq Composite managed to post modest gains, the Dow Jones Industrial Average and S&P 500 were both lower. Sea Limited (NYSE: SE) raised some concerns about the strength of consumers in the Asia-Pacific region, while shareholders in Horizon Therapeutics (NASDAQ: HZNP) had to deal with a threat that could bring hopes for a lucrative acquisition to a grinding halt. Shares of Sea Limited dropped 15% on Tuesday morning following the release of the Southeast Asian e-commerce and video game specialist's latest financial results.
US regulators have warned that “rampant consolidation” in the pharmaceuticals industry is pushing up prices for patients as the Federal Trade Commission sued to block Amgen’s $28.3bn deal to acquire Horizon Therapeutics. The lawsuit marks the first time in more than a decade that the US antitrust regulator has sought to block a deal in the pharmaceutical sector. Shares in Horizon, which is based in Ireland, were down nearly 16 per cent on Tuesday morning in New York.
The regulator said its decision "sends a clear signal to the market" about consolidation in the pharmaceutical market, though analysts expect the deal will still go through despite delays.